{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of October 2023): No\nDescription: No plan"],"condition":["Gastrointestinal Neoplasms","Pancreatic cancer","Colorectal cancer","Gastrointestinal Cancer","Gastric cancer","Esophageal cancer"],"disease":["Gastrointestinal Neoplasms","Colorectal Cancer","Gastric Cancer","Gastrointestinal Cancer","Esophageal Cancer","Pancreatic Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/107815"],"study_start_month":["10"],"keyword":["Gastroesophageal cancer","Capecitabine","Biliary tract cancers"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","description":"This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.","dates":{"creation":"2023-10-15"},"accession":"107815","cross_references":{"ClinicalTrials___gov":["NCT06065371"]}}